

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 11	CA/CAPLUS - Expanded patent coverage to include Russia (Federal Institute of Industrial Property)
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

10/797,244 .

FILE 'HOME' ENTERED AT 14:14:42 ON 25 JAN 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:14:52 ON 25 JAN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JAN 2005 HIGHEST RN 819046-01-0

DICTIONARY FILE UPDATES: 23 JAN 2005 HIGHEST RN 819046-01-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\STNEXP4\QUERIES\10797244-N1.str



chain nodes :

15 17 18 19

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

3-15 5-7 10-17 17-18 18-19

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11

exact/norm bonds :

1-2 1-6 2-3 3-4 3-15 4-5 5-6 5-7 7-8 7-11 8-9 9-10 10-11 10-17 17-18 18-19

10/797,244

G1:N,CH

G2:H,NH2

G3:O,S,CH2,SO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 15:CLASS 17:CLASS 18:CLASS 19:Atom

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 N,CH

G2 H,NH2

G3 O,S,CH2,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:15:15 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 321 TO ITERATE

100.0% PROCESSED 321 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5346 TO 7494

PROJECTED ANSWERS: 6 TO 266

10/797,244


L3

6 SEA SSS SAM L1

=> d scan

10/797,244

L3 6 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrimidine, 2-[4-[3-[4-(4-fluorophenyl)-1-piperazinyl]propyl]-5-methyl-1H-
pyrazol-1-yl]- (9CI)
MF C21 H25 F N6
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5


10/797,244

L3 6 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrimidine, 2-[4-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]-5-methyl-1H-
pyrazol-1-yl]-, monohydrochloride (9CI)
MF C19 H21 Cl N6 . Cl H




10/797,244

L3 6 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrimidine, 2-[4-[3-[4-(4-fluorophenyl)-1-piperazinyl]propyl]-5-methyl-1H-
pyrazol-1-yl]-, monohydrochloride (9CI)
MF C21 H25 F N6 . Cl H



10/797,244


L3 6 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Pyrazol-5-ol, 1-(2-pyridinyl)-4-[[2-(trifluoromethyl)phenyl]methyl]-
(9CI)
MF C16 H12 F3 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/797,244


L3 6 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-1,2,4-Triazole-1-carboxamide, 3-[[3,5-dimethyl-1-(2-pyridinyl)-1H-
pyrazol-4-yl]sulfonyl]-N,N-diethyl- (9CI)
MF C17 H21 N7 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/797,244

L3 6 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Thieno[2,3-d]pyrimidine-5-carboxylic acid, 6-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-, methyl ester (9CI)
MF C23 H25 N5 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10/797,244

=> s 11 sss ful

FULL SEARCH INITIATED 14:15:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6654 TO ITERATE

100.0% PROCESSED 6654 ITERATIONS
SEARCH TIME: 00.00.01

151 ANSWERS

L4 151 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.33

161.54

FILE 'CAPLUS' ENTERED AT 14:15:42 ON 25 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jan 2005 VOL 142 ISS 5
FILE LAST UPDATED: 24 Jan 2005 (20050124/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 14

L5 29 L4

=> d 15 1-29 bib hitstr

10/797,244

L5 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:841775 CAPLUS
DN 141:350163
TI Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists
IN Schiemann, Kai; Ackermann, Karl-August; Arlt, Michael; Finsinger, Dirk; Schadt, Oliver; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 102 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	-----	-----	-----	-----
PI	DE 10315572	A1	20041014	DE 2003-10315572	20030405
	WO 2004089931	A1	20041021	WO 2004-EP2353	20040308
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI DE 2003-10315572 A 20030405

OS MARPAT 141:350163

IT **774585-19-2P 774585-32-9P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)


RN 774585-19-2 CAPLUS

CN Piperazine, 1-[2-(2,4-difluorophenyl)ethyl]-4-[[5-(2-fluorophenyl)-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 774585-32-9 CAPLUS
CN Piperazine, 1-[2-(4-fluorophenyl)ethyl]-4-[[5-(2-fluorophenyl)-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




L5 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:633936 CAPLUS
 DN 141:174183
 TI Preparation of thienopyridazinones as immunosuppressive agents.
 IN Guile, Simon David; Ingall, Anthony Howard
 PA Astrazeneca Ab, Swed.
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004065395	A1	20040805	WO 2004-SE53	20040115
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ				
PRAI	SE 2003-117	A	20030117		
	SE 2003-118	A	20030117		
OS	MARPAT 141:174183				
IT	732305-61-2P 732305-62-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of thienopyridazinones as immunosuppressive agents.)				
RN	732305-61-2 CAPLUS				
CN	4-Isloxazolidinol, 2-[[6-[[3,5-dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-, (4S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 732305-62-3 CAPLUS
 CN 4-Isloxazolidinol, 2-[[6-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 732305-69-0P 732305-70-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thienopyridazinones as immunosuppressive agents.)

RN 732305-69-0 CAPLUS

CN Isoxazolidine, 4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-[[6-[[3,5-dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 732305-70-3 CAPLUS

CN Isoxazolidine, 4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-[[6-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/797,244

L5 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:633935 CAPLUS
DN 141:174182
TI Preparation of thienopyrimidinediones as immunosuppressive agents.
IN Guile, Simon David
PA Astrazeneca Ab, Swed.
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004065394	A1	20040805	WO 2004-SE52	20040115
	W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			
PRAI	SE 2003-119	A	20030117		
OS	MARPAT 141:174182				
IT	733809-51-3P 733809-69-3P 733810-35-0P 733810-37-2P 733810-41-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of thienopyrimidinediones as immunosuppressive agents.)				
RN	733809-51-3 CAPLUS				
CN	4-Isloxazolidinol, 2-[[6-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-, (4S)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 733809-69-3 CAPLUS
CN 4-Isloxazolidinol, 2-[[6-[[3,5-dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-

dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-methyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 733810-35-0 CAPLUS

CN 4-Isoxazolidinol, 4-methyl-2-[[[1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-6-[[5-methyl-1-(2-pyrimidinyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 733810-37-2 CAPLUS

CN 4-Isoxazolidinol, 2-[[[6-[[3,5-dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-ethyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 733810-41-8 CAPLUS

CN 4-Isoxazolidinol, 2-[[6-[[1-(1,2-dihydro-2-oxo-4-pyrimidinyl)-3,5-dimethyl-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-4-ethyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 733810-93-0P 733810-94-1P 733810-98-5P


733810-99-6P 733811-45-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thienopyrimidinediones as immunosuppressive agents.)


RN 733810-93-0 CAPLUS

CN Thieno[2,3-d]pyrimidine-5-carboxylic acid, 6-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-, methyl ester (9CI) (CA INDEX NAME)




RN 733810-94-1 CAPLUS

CN Thieno[2,3-d]pyrimidine-5-carboxylic acid, 6-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 733810-98-5 CAPLUS

CN Thieno[2,3-d]pyrimidine-5-carboxylic acid, 6-[[3,5-dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 733810-99-6 CAPLUS


CN Thieno[2,3-d]pyrimidine-5-carboxylic acid, 6-[[3,5-dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 733811-45-5 CAPLUS

CN Thieno[2,3-d]pyrimidine-5-carboxylic acid, 6-[[1-(1,2-dihydro-2-oxo-4-pyrimidinyl)-3,5-dimethyl-1H-pyrazol-4-yl]methyl]-1,2,3,4-tetrahydro-3-methyl-1-(1-methylethyl)-2,4-dioxo- (9CI) (CA INDEX NAME)




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:633934 CAPLUS
 DN 141:174194
 TI Preparation of thienopyridazinones as immunosuppressive agents.
 IN Cooper, Martin Edward; Guile, Simon David; Ingall, Anthony Howard; Rasul, Rukhsana Tasneem
 PA Astrazeneca Ab, Swed.
 SO PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004065393	A1	20040805	WO 2004-SE51	20040115
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ				
PRAI	SE 2003-120	A	20030117		
OS	MARPAT 141:174194				
IT	733745-25-0P 733745-26-1P 733745-28-3P 733745-29-4P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of thienopyridazinones as immunosuppressive agents.)				
RN	733745-25-0 CAPLUS				
CN	4-Isloxazolidinol, 2-[[2-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-7-ethyl-4,5-dihydro-5-methyl-4-oxothieno[2,3-d]pyridazin-3-yl]carbonyl]-, (4S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 733745-26-1 CAPLUS
 CN 4-Isloxazolidinol, 2-[[2-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-7-ethyl-4,5-dihydro-5-methyl-4-oxothieno[2,3-d]pyridazin-3-yl]carbonyl]-4-methyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 733745-28-3 CAPLUS

CN 4-Isloxazolidinol, 2-[[2-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl)methyl]-4,5-dihydro-5-methyl-7-(1-methylethyl)-4-oxothieno[2,3-d]pyridazin-3-yl]carbonyl]-4-methyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 733745-29-4 CAPLUS

CN 4-Isloxazolidinol, 2-[[2-[[3,5-dimethyl-1-(2-pyrimidinyl)-1H-pyrazol-4-yl)methyl]-4,5-dihydro-5-methyl-7-(1-methylethyl)-4-oxothieno[2,3-d]pyridazin-3-yl]carbonyl]-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 733745-75-0P 733745-76-1P 733745-82-9P
733745-83-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thienopyridazinones as immunosuppressive agents.)


RN 733745-75-0 CAPLUS

CN Thieno[2,3-d]pyridazin-4(5H)-one, 3-bromo-2-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-7-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 733745-76-1 CAPLUS


CN Thieno[2,3-d]pyridazine-3-carboxylic acid, 2-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-7-ethyl-4,5-dihydro-5-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 733745-82-9 CAPLUS


10/797,244

CN Thieno[2,3-d]pyridazin-4(5H)-one, 3-bromo-2-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-5-methyl-7-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 733745-83-0 CAPLUS


CN Thieno[2,3-d]pyridazine-3-carboxylic acid, 2-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-4,5-dihydro-5-methyl-7-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/797,244

L5 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:112122 CAPLUS
DN 139:239629
TI CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists
AU Datar, Prasanna; Desai, Prashant; Coutinho, Evans; Iyer, Krishna
CS Department of Pharmaceutical Chemistry, Bombay College of Pharmacy,
Mumbai, 400 098, India
SO Journal of Molecular Modeling (2002), 8(10), 290-301
CODEN: JMMOFK; ISSN: 0948-5023
URL: <http://link.springer.de/link/service/journals/00894/contents/02/00097/paper/s00894-002-0097-6.pdf>
PB Springer-Verlag
DT Journal; (online computer file)
LA English
IT **152713-36-5**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists)
RN 152713-36-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-pyridinyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:736255 CAPLUS

DN 137:263065

TI Preparation of triazaspiro[5.5]undecane derivatives as active ingredients in remedies for inflammatory diseases

IN Habashita, Hiromu; Hamano, Shinichi; Shibayama, Shiro; Takaoka, Yoshikazu

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 379 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074770	A1	20020926	WO 2002-JP2554	20020318
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	CA 2440264	AA	20020926	CA 2002-2440264	20020318
	EP 1378510	A1	20040107	EP 2002-705301	20020318
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
	BR 2002008167	A	20040309	BR 2002-8167	20020318
	JP 3558079	B2	20040825	JP 2002-573779	20020318
	NO 2003004148	A	20031114	NO 2003-4148	20030917
	US 2004082584	A1	20040429	US 2003-472555	20030922
	JP 2004196822	A2	20040715	JP 2004-66592	20040310
PRAI	JP 2001-79610	A	20010319		
	JP 2001-160251	A	20010529		
	JP 2002-573779	A3	20020318		
	WO 2002-JP2554	W	20020318		

OS MARPAT 137:263065

IT **461020-93-9P 461023-13-2P 461442-06-8P 461443-20-9P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazaspiro[5.5]undecane derivs. as active ingredients in remedies for inflammatory diseases)

RN 461020-93-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 461023-13-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 461442-06-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 461443-20-9 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-, (3R)- (9CI) (CA INDEX NAME)

10/797,244

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:736254 CAPLUS

DN 137:263064

TI Preparation of triazaspiro[5.5]undecane derivatives as the active ingredients useful in prevention or as remedy for HIV infection

IN Mitsuya, Hiroaki; Maeda, Kenji; Shibayama, Shiro; Takaoka, Yoshikazu

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 680 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074769	A1	20020926	WO 2002-JP2553	20020318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2441162	AA	20020926	CA 2002-2441162	20020318
	EP 1378509	A1	20040107	EP 2002-705300	20020318
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002008229	A	20040309	BR 2002-8229	20020318
	NO 2003004149	A	20031119	NO 2003-4149	20030917
	US 2004106619	A1	20040603	US 2003-472626	20030922
PRAI	JP 2001-79611	A	20010319		
	WO 2002-JP2553	W	20020318		

OS MARPAT 137:263064

IT 343274-90-8P 343275-91-2P 343276-74-4P

461020-93-9P 461023-13-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazaspiro[5.5]undecane derivs. as the active ingredients in prevention or remedy of HIV infection)

RN 343274-90-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-3-(2-methylpropyl)-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 343275-91-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-
[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-, dihydrochloride,
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 343276-74-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[3,5-dimethyl-1-(2-
pyridinyl)-1H-pyrazol-4-yl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-,
dihydrochloride, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 461020-93-9 CAPLUS

10/797,244

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 461023-13-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(R)-cyclohexylhydroxymethyl]-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:293632 CAPLUS

DN 136:325538

TI Preparation of pyrazoles for the treatment of viral diseases

IN Dymock, Brian William; Jones, Philip Stephen; Merrett, John Herbert; Parratt, Martin John

PA F. Hoffmann-La Roche Ag, Switz.

SO PCT Int. Appl., 108 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002030907	A1	20020418	WO 2001-EP11474	20011004	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	US 2003018197	A1	20030123	US 2001-956656	20010920	
	US 6699887	B2	20040302			
	CA 2423515	AA	20020418	CA 2001-2423515	20011004	
	AU 2002021651	A5	20020422	AU 2002-21651	20011004	
	BR 2001014483	A	20030701	BR 2001-14483	20011004	
	EP 1326843	A1	20030716	EP 2001-986680	20011004	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	JP 2004511469	T2	20040415	JP 2002-534293	20011004	
	NO 2003001615	A	20030523	NO 2003-1615	20030409	
	US 2004192752	A1	20040930	US 2004-766712	20040127	
PRAI	GB 2000-24795	A	20001010			
	US 2001-956656	A3	20010920			
	WO 2001-EP11474	W	20011004			
OS	MARPAT 136:325538					
IT	412326-26-2P					
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)					
	(preparation of pyrazoles as inhibitors of the HIV reverse transcriptase)					
RN	412326-26-2 CAPLUS					
CN	Pyridine, 2-[5-[(3,5-dichlorophenyl)thio]-3-methyl-4-(phenylmethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)					



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:851126 CAPLUS

DN 135:371760

TI Preparation of pyrazolylpyrimidines and analogs as TNF- α signaling modulators

IN Sneddon, Scott F.; Kane, John L.; Hirth, Bradford H.; Vinick, Fred; Qiao, Shuang; Nahill, Sharon R.

PA Genzyme Corporation, USA

SO PCT Int. Appl., 108 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001087849	A2	20011122	WO 2001-US15027	20010510
	WO 2001087849	A3	20020606		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2408408	AA	20011122	CA 2001-2408408	20010510
	US 2002119988	A1	20020829	US 2001-852965	20010510
	EP 1294699	A2	20030326	EP 2001-933253	20010510
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003533515	T2	20031111	JP 2001-584245	20010510
	BR 2001011158	A	20040406	BR 2001-11158	20010510
	NO 2002005405	A	20030109	NO 2002-5405	20021111
	US 2004171617	A1	20040902	US 2004-797244	20040310
PRAI	US 2000-203784P	P	20000512		
	US 2000-205213P	P	20000518		
	US 2001-852965	A3	20010510		
	WO 2001-US15027	W	20010510		
OS	MARPAT 135:371760				
IT	374080-77-0P 374080-78-1P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of pyrazolylpyrimidines and analogs as TNF- α signaling modulators)				
RN	374080-77-0 CAPLUS				
CN	Benzenemethanol, 4-[[3,5-dimethyl-1-[4-(2-pyridinyl)-2-pyrimidinyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)				



RN 374080-78-1 CAPLUS

CN Benzaldehyde, 4-[[3,5-dimethyl-1-[4-(2-pyridinyl)-2-pyrimidinyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




IT 374080-70-3P 374080-71-4P 374080-72-5P
 374080-73-6P 374080-74-7P 374080-75-8P
 374080-76-9P 374080-79-2P 374080-80-5P
 374080-81-6P 374080-82-7P 374080-83-8P
 374080-84-9P 374080-85-0P 374080-86-1P
 374080-87-2P 374080-88-3P 374080-89-4P
 374080-90-7P 374080-91-8P 374080-92-9P
 374080-93-0P 374080-94-1P 374080-95-2P
 374080-96-3P 374080-97-4P 374080-98-5P
 374080-99-6P 374081-00-2P 374081-01-3P
 374081-02-4P 374081-03-5P 374081-16-0P
 374081-17-1P 374081-18-2P 374081-19-3P
 374081-20-6P 374081-21-7P 374081-23-9P
 374081-24-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolylpyrimidines and analogs as TNF- α signaling modulators)

RN 374080-70-3 CAPLUS


CN Pyrimidine, 2-(3,5-dimethyl-4-phenoxy-1H-pyrazol-1-yl)-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

10/797,244




RN 374080-71-4 CAPLUS

CN Pyrimidine, 2-[4-(4-chlorophenoxy)-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-72-5 CAPLUS

CN Pyrimidine, 2-[4-(4-fluorophenoxy)-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-73-6 CAPLUS

CN Pyrimidine, 2-[4-(4-methoxyphenoxy)-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-74-7 CAPLUS

CN Pyrimidine, 2-[3,5-dimethyl-4-[4-(1-methylethyl)phenoxy]-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-75-8 CAPLUS

CN Pyrimidine, 2-[3,5-dimethyl-4-[4-(trifluoromethyl)phenoxy]-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-76-9 CAPLUS

CN Pyrimidine, 2-[3,5-dimethyl-4-[4-(trifluoromethoxy)phenoxy]-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-79-2 CAPLUS

CN Morpholine, 4-[[4-[[3,5-dimethyl-1-[4-(2-pyridinyl)-2-pyrimidinyl]-1H-pyrazol-4-yl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 374080-80-5 CAPLUS


CN Isoquinoline, 2-[[4-[[3,5-dimethyl-1-[4-(2-pyridinyl)-2-pyrimidinyl]-1H-pyrazol-4-yl]oxy]phenyl]methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 374080-81-6 CAPLUS

CN Pyrimidine, 2-[3,5-dimethyl-4-[4-[[4-(phenylmethyl)-1-


piperazinyl]methyl]phenoxy]-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-82-7 CAPLUS

CN Pyrimidine, 2-[4-[4-[[4-(2-fluorophenyl)-1-piperazinyl]methyl]phenoxy]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 374080-83-8 CAPLUS

CN Pyrimidine, 2-[4-(4-chlorophenoxy)-3,5-dimethyl-1H-pyrazol-1-yl]-4-pyrazinyl- (9CI) (CA INDEX NAME)




RN 374080-84-9 CAPLUS

CN Pyrimidine, 2-[4-[(4-chlorophenyl)methoxy]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-85-0 CAPLUS

CN Pyrimidine, 2-[3,5-dimethyl-4-(phenylthio)-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-86-1 CAPLUS

CN Pyrimidine, 2-[4-[(2-chlorophenyl)thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-87-2 CAPLUS

CN Pyrimidine, 2-[4-[(3-chlorophenyl)thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-88-3 CAPLUS

CN Pyrimidine, 2-[4-[(4-chlorophenyl)thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-89-4 CAPLUS

CN Pyrimidine, 2-[4-[(4-fluorophenyl)thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 374080-90-7 CAPLUS


CN Pyrimidine, 2-[4-[(4-methoxyphenyl)thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 374080-91-8 CAPLUS


CN Pyrimidine, 2-[4-[(3,4-dichlorophenyl)thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

10/797,244




RN 374080-92-9 CAPLUS

CN Pyrimidine, 2-[4-[(4-chlorophenyl)thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 374080-93-0 CAPLUS


CN Pyrimidine, 2-[4-[(4-chlorophenyl)thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 374080-94-1 CAPLUS


CN Pyrimidine, 2-[3,5-dimethyl-4-[(phenylmethyl)thio]-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

10/797,244




RN 374080-95-2 CAPLUS

CN Pyrimidine, 2-[4-[[2-(2-chlorophenyl)methyl]thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 374080-96-3 CAPLUS


CN Pyrimidine, 2-[4-[[2-(4-chlorophenyl)methyl]thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 374080-97-4 CAPLUS


CN Pyrimidine, 2-[4-[[2-(4-fluorophenyl)methyl]thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

10/797,244




RN 374080-98-5 CAPLUS

CN Pyrimidine, 2-[3,5-dimethyl-4-[[4-(4-methylphenyl)methyl]thio]-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374080-99-6 CAPLUS

CN Pyrimidine, 2-[4-[[4-(4-methoxyphenyl)methyl]thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374081-00-2 CAPLUS

CN Pyrimidine, 2-[3,5-dimethyl-4-[[[4-(trifluoromethoxy)phenyl]methyl]thio]-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374081-01-3 CAPLUS

CN Pyrimidine, 2-[4-[[[4-(chlorophenyl)methyl]sulfonyl]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374081-02-4 CAPLUS

CN 2,2'-Bipyridine, 6-[4-(4-chlorophenoxy)-3,5-dimethyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 374081-03-5 CAPLUS

CN 2,2'-Bipyridine, 6-[4-[(4-chlorophenyl)methyl]thio]-3,5-dimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 374081-16-0 CAPLUS


CN 1,3,5-Triazin-2-amine, 4-[4-[(4-chlorophenyl)thio]-3,5-dimethyl-1H-pyrazol-1-yl]-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



10/797,244


RN 374081-17-1 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-[4-[(4-chlorophenyl)sulfonyl]-3,5-dimethyl-1H-pyrazol-1-yl]-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374081-18-2 CAPLUS

CN 1,3,5-Triazine, 2-[4-[(4-chlorophenyl)thio]-3,5-dimethyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374081-19-3 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-[3,5-dimethyl-4-(phenylmethyl)-1H-pyrazol-1-yl]-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 374081-20-6 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-[4-[2-(4-chlorophenyl)ethyl]-3,5-dimethyl-1H-pyrazol-1-yl]-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 374081-21-7 CAPLUS


CN 1,3,5-Triazin-2-amine, 4-[3,5-dimethyl-4-(3-phenylpropyl)-1H-pyrazol-1-yl]-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 374081-23-9 CAPLUS


CN 3H-Pyrazol-3-one, 4-[(4-chlorophenyl)thio]-1,2-dihydro-5-methyl-1-[4-(2-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/797,244




RN 374081-24-0 CAPLUS

CN Pyrimidine, 2-[4-[(4-chlorophenyl)thio]-3-methoxy-5-methyl-1H-pyrazol-1-yl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



10/797,244

L5 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:794586 CAPLUS
DN 136:200136
TI Hydrazinolytic recyclization of (Z)-3-acetyl-2-methyl-2,3-dihydro-1,4-benzodioxin-2-ol
AU Dzvinchuk, I. V.; Lozinskii, M. O.
CS Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Kiev, 253660, Ukraine
SO Chemistry of Heterocyclic Compounds (New York, NY, United States) (Translation of Khimiya Geterotsiklicheskikh Soedinenii) (2001), 37(4), 459-462
CODEN: CHCCAL; ISSN: 0009-3122
PB Kluwer Academic/Consultants Bureau
DT Journal
LA English
OS CASREACT 136:200136
IT **305854-40-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (o-hydroxyphenoxy)-substituted pyrazoles by condensation of hydrazines with an acetylmethyldihydrobenzodioxinol)
RN 305854-40-4 CAPLUS
CN Phenol, 2-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:416939 CAPLUS

DN 135:46203

TI Preparation and effect of triazaspiro[5.5]undecane derivatives as active ingredients in remedy for inflammatory diseases

IN Habashita, Hiromu; Hamano, Shinichi; Shibayam, Shiro; Takaoka, Yoshikazu

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 1149 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2001040227	A1	20010607	WO 2000-JP8517	20001201	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	CA 2394679	AA	20010607	CA 2000-2394679	20001201	
	AU 2001016506	A5	20010612	AU 2001-16506	20001201	
	EP 1236726	A1	20020904	EP 2000-979050	20001201	
	EP 1236726	B1	20041201			
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	AT 283854	E	20041215	AT 2000-979050	20001201	
	ZA 2002004203	A	20030827	ZA 2002-4203	20020527	
	NO 2002002609	A	20020726	NO 2002-2609	20020531	
	US 2004097511	A1	20040520	US 2003-148382	20030508	
PRAI	JP 1999-344967	A	19991203			
	JP 2000-18673	A	20000127			
	JP 2000-27968	A	20000204			
	JP 2000-147882	A	20000519			
	WO 2000-JP8517	W	20001201			

OS MARPAT 135:46203

IT 342912-66-7P 342913-52-4P 342914-23-2P

343274-90-8P 343275-91-2P 343276-74-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and effect of triazaspiro[5.5]undecane derivs. as active ingredients in inflammatory disease therapy)

RN 342912-66-7 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-3-(2-methylpropyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342913-52-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342914-23-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, (3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 343274-90-8 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-3-(2-methylpropyl)-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 343275-91-2 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-, dihydrochloride, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 343276-74-4 CAPLUS

CN 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-9-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methyl]-3-[(1R)-1-hydroxy-2-methylpropyl]-, dihydrochloride, (3R)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl


RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/797,244

ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/797,244

L5 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:813020 CAPLUS
DN 134:128105
TI Miniature single-particle immunoassay for prostate-specific antigen in serum using recombinant Fab fragments
AU Harma, Harri; Tarkkinen, Piia; Soukka, Tero; Lovgren, Timo
CS Department of Biotechnology, University of Turku, Turku, FIN-20520, Finland
SO Clinical Chemistry (Washington, D. C.) (2000), 46(11), 1755-1761
CODEN: CLCHAU; ISSN: 0009-9147
PB American Association for Clinical Chemistry
DT Journal
LA English
IT **321883-66-3D**, europium and terbium complexes
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (fluorescent label for mAb; miniature single-particle immunoassay for prostate-specific antigen in serum using recombinant Fab fragments)
RN 321883-66-3 CAPLUS
CN Glycine, N,N'-[[4-[2-(4-isothiocyanatophenyl)ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-(carboxymethyl)- (9CI) (CA INDEX NAME)




RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:2264 CAPLUS
 DN 132:166203
 TI Synthesis and antitumor activity of novel pyrimidinylpyrazole derivatives
 AU Naito, Hiroyuki; Sugimori, Masamichi; Mitsui, Ikuo; Nakamura, Yoshihide;
 Iwahana, Michio; Ishii, Mineko; Hirotsu, Kenji; Kumazawa, Eiji; Ejima,
 Akio
 CS New Product Research Laboratories IV, Daiichi Pharmaceutical Co., Ltd.,
 Tokyo, 134-8630, Japan
 SO Chemical & Pharmaceutical Bulletin (1999), 47(12), 1679-1684
 CODEN: CPBTAL; ISSN: 0009-2363
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 IT 53345-79-2 53345-96-3 258823-78-8
 258823-80-2 258823-83-5 258823-86-8
 258823-88-0 258823-90-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BIOL (Biological study)
 (preparation and antitumor activity of pyrimidinylpyrazole derivs.)
 RN 53345-79-2 CAPLUS
 CN Pyrimidine, 2-[5-methyl-4-[(4-phenyl-1-piperazinyl)methyl]-1H-pyrazol-1-
 yl]- (9CI) (CA INDEX NAME)




RN 53345-96-3 CAPLUS
 CN Pyrimidine, 2-[5-methyl-4-[3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-1H-
 pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 258823-78-8 CAPLUS

CN Pyrimidine, 2-[4-[2-[4-(2-fluorophenyl)-1-piperazinyl]ethyl]-5-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 258823-80-2 CAPLUS

CN Pyrimidine, 2-[4-[3-[4-(2-fluorophenyl)-1-piperazinyl]propyl]-5-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 258823-83-5 CAPLUS

CN Pyrimidine, 2-[5-methyl-4-[2-(4-phenyl-1-piperazinyl)ethyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 258823-86-8 CAPLUS

CN Pyrimidine, 2-[5-methyl-4-[3-(4-phenyl-1-piperazinyl)propyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 258823-88-0 CAPLUS

CN Pyrimidine, 2-[5-methyl-4-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 258823-90-4 CAPLUS

CN Pyrimidine, 2-[5-methyl-4-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:819049 CAPLUS

DN 132:64173

TI Preparation of labeling reactants for fluorescent labeling of biospecific binding reactants

IN Takalo, Harri; Hovinen, Jari; Mikkala, Veli-matti; Liitti, Pivi; Mikola, Heikki

PA Wallac Oy, Finland

SO Eur. Pat. Appl., 26 pp.


CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 967205	A1	19991229	EP 1999-660100	19990603
	EP 967205	B1	20030917		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6080839	A	20000627	US 1998-104219	19980625
PRAI	US 1998-104219	A	19980625		
OS	CASREACT 132:64173; MARPAT 132:64173				
IT	253137-98-3P 253137-99-4P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(intermediate; preparation of pyridinediylbis(methylenenitrilo)tetrakisacetic acid labeling reactants for fluorescent labeling of biospecific binding reactants in solid phase synthesis)				
RN	253137-98-3 CAPLUS				
CN	Glycine, N,N'-[[4-[2-[4-(2-methoxy-2-oxoethoxy)phenyl]ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)				



RN 253137-99-4 CAPLUS

CN Glycine, N,N'-[[4-[2-[4-(carboxymethoxy)phenyl]ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,1'-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

IT **253137-93-8P**


RL: SPN (Synthetic preparation); PREP (Preparation)
 (target compound; preparation of
 pyridinediylbis(methylenenitrilo)tetrakisacet
 ic acid labeling reactants for fluorescent labeling of biospecific
 binding reactants in solid phase synthesis)


RN 253137-93-8 CAPLUS

CN D-Lysine, N6-[[4-[2-[1,3-bis[6-[[bis[2-(1,1-dimethylethoxy)-2-
 oxoethyl]amino]methyl]-2-pyridinyl]-1H-pyrazol-4-yl]ethyl]phenoxy]acetyl]-
 N2-[(9H-fluoren-9-ylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:587152 CAPLUS

DN 127:205568

TI Preparation of thienylpyrazole derivatives as adrenaline receptor blockers
IN Taguchi, Minoru; Okubo, Taketoshi; Yoshimura, Misa; Hatada, Yuichi; Ota, Tomoki; Tomizawa, Kazuyuki

PA Taisho Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 17 pp.

CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09227555	A2	19970902	JP 1996-29222	19960216
PRAI	JP 1996-29222		19960216		
OS	MARPAT 127:205568				
IT	194545-41-0P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienylpyrazole derivs. as adrenaline receptor blockers)

RN 194545-41-0 CAPLUS

CN Piperazine, 1-(2-methoxyphenyl)-4-[2-[1-(2-pyridinyl)-5-(2-thienyl)-1H-pyrazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1997:374715 CAPLUS
 DN 126:350804
 TI Biospecific binding reactants labeled with luminescent lanthanide chelates and their use
 IN Rodriguez-Ubis, Juan Carlos; Takalo, Harri; Mikkala, Veli-matti
 PA Wallac Oy, Finland; Rodriguez-Ubis, Juan Carlos
 SO Eur. Pat. Appl., 33 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 770610	A1	19970502	EP 1996-660056	19960909
	R: DE, FR, GB				
	US 5859215	A	19990112	US 1995-548174	19951025
PRAI	US 1995-548174	A	19951025		
OS	MARPAT 126:350804				
IT	189805-30-9P 189805-36-5P				

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of luminescent lanthanide pyrazolediylbispyridinediyl and pyridinediylbispyrazolediyl bismethylenenitrilotetrakisacetato chelates for biospecific binding assays)


RN 189805-30-9 CAPLUS

CN Glycine, N,N'-[[4-[2-(4-aminophenyl)ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 189805-36-5 CAPLUS

CN Glycine, N,N'-[[4-[2-(4-aminophenyl)ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-(carboxymethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:205145 CAPLUS

DN 126:199571

TI Preparation of piperazine derivatives as therapeutic agents

IN Kerrigan, Frank; Cheetham, Sharon Crawford; Watts, John Paul

PA Knoll Aktiengesellschaft, Germany; Kerrigan, Frank; Cheetham, Sharon
Crawford; Watts, John Paul

SO PCT Int. Appl., 116 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9703067	A1	19970130	WO 1996-EP2889	19960702
	W: AU, BG, BR, CA, CN, CZ, GE, HU, IL, JP, KR, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9665171	A1	19970210	AU 1996-65171	19960702
	EP 839144	A1	19980506	EP 1996-924846	19960702
	EP 839144	B1	20010919		
	R: DE, FR, GB, IT				
	JP 11508888	T2	19990803	JP 1996-504630	19960702
	ZA 9605923	A	19980112	ZA 1996-5923	19960712
	US 6114334	A	20000905	US 1997-973843	19971217
PRAI	GB 1995-14389	A	19950713		
	GB 1996-6674	A	19960329		
	WO 1996-EP2889	W	19960702		
OS	MARPAT 126:199571				
IT	187794-75-8P 187794-93-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of piperazine derivs. as therapeutic agents)				
RN	187794-75-8 CAPLUS				
CN	1H-Pyrazol-5-amine, 3-cyclopropyl-4-[[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]methyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)				



RN 187794-93-0 CAPLUS

CN 1H-Pyrazol-5-amine, 3-cyclopropyl-4-[[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]methyl]-1-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:314049 CAPLUS

DN 125:58525

TI Herbicidal triazolecarboxamides.

IN Tseng, Chi Ping

PA E. I. Du Pont de Nemours & Co., USA

SO U.S., 100 pp., Cont.-in-part of U.S. Ser. No. 784,343, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5510320	A	19960423	US 1994-211721	19940426
	WO 9309100	A1	19930513	WO 1992-US8822	19921022
	W:			AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, UA, US	
	RW:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG	
PRAI	US 1991-784343	B2	19911029		
	WO 1992-US8822	W	19921022		


OS MARPAT 125:58525

IT **151114-79-3P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of herbicidal triazolecarboxamides)

RN 151114-79-3 CAPLUS

CN 1H-1,2,4-Triazole-1-carboxamide, 3-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]sulfonyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



L5 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:134381 CAPLUS

DN 120:134381

TI Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates

AU Ashton, Wallace T.; Hutchins, Steven M.; Greenlee, William J.; Doss, George A.; Chang, Raymond S. L.; Lotti, Victor J.; Faust, Kristie A.; Chen, Tsing Bau; Zingaro, Gloria J.; et al.

CS Merck Res. Lab., Rahway, NJ, 07065, USA

SO Journal of Medicinal Chemistry (1993), 36(23), 3595-605

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English


IT **138733-03-6P 152713-36-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and angiotensin II antagonist activity of)


RN 138733-03-6 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-pyridinyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 152713-36-5 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-pyridinyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT **152713-67-2P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclization of, with azide, triazole derivative from)

10/797,244


RN 152713-67-2 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1993:649954 CAPLUS
 DN 119:249954
 TI Herbicidal triazolecarboxamides
 IN Tseng, Chi Ping
 PA du Pont de Nemours, E. I., and Co., USA
 SO PCT Int. Appl., 237 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9309100	A1	19930513	WO 1992-US8822	19921022
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	CN 1071924	A	19930512	CN 1992-112827	19920923
	ZA 9207272	A	19940323	ZA 1992-7272	19920923
	AU 9228716	A1	19930607	AU 1992-28716	19921022
	EP 610314	A1	19940817	EP 1992-922261	19921022
	R: DE, ES, FR, GB, IT				
	US 5510320	A	19960423	US 1994-211721	19940426
PRAI	US 1991-784343	A2	19911029		
	WO 1992-US8822	A	19921022		
OS	MARPAT 119:249954				
IT	151114-79-3P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and herbicidal activity of)				
RN	151114-79-3 CAPLUS				
CN	1H-1,2,4-Triazole-1-carboxamide, 3-[[3,5-dimethyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]sulfonyl]-N,N-diethyl- (9CI) (CA INDEX NAME)				



L5 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1992:565941 CAPLUS
 DN 117:165941
 TI Preparation of pyrazolecarboxylic acid derivatives as herbicides.
 IN Yoshimura, Takumi; Myazaki, Masahiro; Shimizu, Kuniaki; Hirata, Michi
 PA Kumiai Chemical Industry Co., Ltd., Japan; Ihara Chemical Industry Co.,
 Ltd.
 SO Jpn. Kokai Tokkyo Koho, 11 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04145081	A2	19920519	JP 1990-268611	19901006
PRAI	JP 1990-268611		19901006		


OS MARPAT 117:165941

IT **143727-52-0P 143727-66-6P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except
 adverse); BSU (Biological study, unclassified); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as herbicide)


RN 143727-52-0 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 4-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-3-
 methyl-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 143727-66-6 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 4-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-3-
 methyl-1-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:511598 CAPLUS

DN 117:111598

TI Preparation of trans-6-[2-(heteroarylpyrazol-4-yl)ethyl- or -ethenyl]tetrahydro-4-hydroxypyran-2-ones as inhibitors of cholesterol biosynthesis

IN Picard, Joseph A.; Roth, Bruce D.; Sliskovic, Drago R.

PA Warner-Lambert Co., USA

SO U.S., 16 pp. Cont.-in-part of U.S. 4,957,971.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5102893	A	19920407	US 1990-540047	19900619
	US 4808621	A	19890228	US 1987-48473	19870518
	US 4957971	A	19900918	US 1988-280756	19881206
PRAI	US 1986-882327	B2	19860707		
	US 1987-48473	A2	19870518		
	US 1988-280756	A2	19881206		


OS MARPAT 117:111598

IT **142407-02-1P**RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as HMG-CoA reductase inhibitor)

RN 142407-02-1 CAPLUS


CN 2H-Pyran-2-one, 6-[2-[5-(4-fluorophenyl)-3-(1-methylethyl)-1-(2-pyridinyl)-1H-pyrazol-4-yl]ethyl]tetrahydro-4-hydroxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L5 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1992:255526 CAPLUS
DN 116:255526
TI Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones
AU Sliskovic, D. R.; Blankley, C. J.; Krause, B. R.; Newton, R. S.; Picard, J. A.; Roark, W. H.; Roth, B. D.; Sekerke, C.; Shaw, M. K.; Stanfield, R. L.
CS Parke-Davis Pharm. Res. Div., Warner-Lambert Co., Ann Arbor, MI, 48105, USA
SO Journal of Medicinal Chemistry (1992), 35(11), 2095-103
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
IT **114433-74-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cholesterol biosynthesis inhibiting activity of)
RN 114433-74-8 CAPLUS
CN 2H-Pyran-2-one, 6-[2-[5-(4-fluorophenyl)-3-(1-methylethyl)-1-(2-pyridinyl)-1H-pyrazol-4-yl]ethyl]tetrahydro-4-hydroxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L5 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1992:194308 CAPLUS
 DN 116:194308
 TI Preparation of 1-(2-pyridyl or -pyrimidyl)5-hydroxypyrazoles as fungicidal materials preservatives
 IN Sasse, Klaus; Schwamborn, Michael; Wachtler, Peter; Frie, Monika; Ludwig, Georg Wilhelm; Paulus, Wilfried; Schmitt, Hans Georg
 PA Bayer A.-G., Germany
 SO Ger. Offen., 14 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4023488	A1	19920130	DE 1990-4023488	19900724
	EP 469357	A1	19920205	EP 1991-111537	19910711
	R: AT, CH, DE, DK, FR, GB, IT, LI, SE				
	US 5175176	A	19921229	US 1991-731680	19910717
	JP 04234385	A2	19920824	JP 1991-203739	19910719
	US 5292744	A	19940308	US 1992-929652	19920812
PRAI	DE 1990-4023488	A	19900724		
	US 1991-731680	A3	19910717		
OS	MARPAT 116:194308				
IT	140397-99-5P 140398-00-1P 140398-01-2P 140398-02-3P 140398-04-5P 140398-05-6P 140398-06-7P 140398-07-8P 140398-08-9P 140398-09-0P 140398-10-3P 140398-11-4P 140398-12-5P 140398-13-6P 140398-14-7P 140398-15-8P 140398-16-9P 140398-29-4P 140398-33-0P 140398-34-1P 140398-48-7P 140398-60-3P 140421-89-2P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as microbicidal materials preservative)				
RN	140397-99-5 CAPLUS				
CN	1H-Pyrazol-5-ol, 4-(phenylmethyl)-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)				




RN 140398-00-1 CAPLUS
 CN 1H-Pyrazol-5-ol, 1-(2-pyridinyl)-4-[[2-(trifluoromethyl)phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 140398-01-2 CAPLUS

CN 1H-Pyrazol-5-ol, 4-[(2-chlorophenyl)methyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 140398-02-3 CAPLUS


CN 1H-Pyrazol-5-ol, 4-[(2,4-dichlorophenyl)methyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 140398-04-5 CAPLUS
 CN 1H-Pyrazol-5-ol, 4-[(4-methylphenyl)methyl]-1-(2-pyridinyl)- (9CI) (CA
 INDEX NAME)




RN 140398-05-6 CAPLUS
 CN 1H-Pyrazol-5-ol, 4-[(4-methoxyphenyl)methyl]-1-(2-pyridinyl)- (9CI) (CA
 INDEX NAME)




RN 140398-06-7 CAPLUS

CN 1H-Pyrazol-5-ol, 4-[(1,3-benzodioxol-5-ylmethyl)-1-(2-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 140398-07-8 CAPLUS

CN 1H-Pyrazol-5-ol, 4-[(3-chlorophenyl)methyl]-1-(2-pyridinyl)- (9CI) (CA
INDEX NAME)




RN 140398-08-9 CAPLUS

CN 1H-Pyrazol-5-ol, 4-[(4-bromophenyl)methyl]-1-(2-pyridinyl)- (9CI) (CA
INDEX NAME)



RN 140398-09-0 CAPLUS


CN 1H-Pyrazol-5-ol, 4-[(3-methylphenyl)methyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 140398-10-3 CAPLUS


CN 1H-Pyrazol-5-ol, 4-[[4-(1,1-dimethylethyl)phenyl]methyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)

10/797,244




RN 140398-11-4 CAPLUS

CN 1H-Pyrazol-5-ol, 4-(phenylmethyl)-1-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 140398-12-5 CAPLUS

CN 1H-Pyrazol-5-ol, 4-[(2-chlorophenyl)methyl]-1-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 140398-13-6 CAPLUS

CN 1H-Pyrazol-5-ol, 1-(2-pyrimidinyl)-4-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 140398-14-7 CAPLUS
 CN 1H-Pyrazol-5-ol, 4-[(3-methylphenyl)methyl]-1-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 140398-15-8 CAPLUS
 CN 1H-Pyrazol-5-ol, 4-[(2,4-dichlorophenyl)methyl]-1-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)

10/797,244




RN 140398-16-9 CAPLUS

CN 1H-Pyrazol-5-ol, 4-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-1-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 140398-29-4 CAPLUS

CN 1H-Pyrazol-5-ol, 4-[(phenylmethyl)thio]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 140398-33-0 CAPLUS

CN 1H-Pyrazol-5-ol, 4-(1-naphthalenylmethyl)-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 140398-34-1 CAPLUS

CN 1H-Pyrazol-5-ol, 3-phenyl-4-(phenylmethyl)-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 140398-48-7 CAPLUS


CN 1H-Pyrazol-5-ol, 3-methyl-4-(phenylmethyl)-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 140398-60-3 CAPLUS


10/797,244

CN 1H-Pyrazol-5-ol, 3-methyl-4-(phenylmethyl)-1-(2-pyrimidinyl)- (9CI) (CA
INDEX NAME)



RN 140421-89-2 CAPLUS

CN 1H-Pyrazol-5-ol, 4-[(4-methoxyphenyl)methyl]-1-(2-pyrimidinyl)- (9CI) (CA
INDEX NAME)



L5 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:106284 CAPLUS

DN 116:106284

TI Preparation of substituted pyrazoles, isoxazoles and isothiazoles as
angiotensin II antagonists

IN Allen, Eric E.; Greenlee, William J.; MacCoss, Malcolm; Ashton, Wallace T.

PA Merck and Co., Inc., USA

SO PCT Int. Appl., 171 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9115479	A1	19911017	WO 1991-US1952	19910327
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	CA 2079343	AA	19911001	CA 1991-2079343	19910327
	EP 523141	A1	19930120	EP 1991-907490	19910327
	R: CH, DE, FR, GB, IT, LI, NL				
	JP 05505822	T2	19930826	JP 1991-507326	19910327
PRAI	US 1990-501469	A	19900330		
	WO 1991-US1952	W	19910327		

OS MARPAT 116:106284

IT **138733-03-6P**RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as angiotensin II inhibitor)

RN 138733-03-6 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-pyridinyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:185784 CAPLUS

DN 114:185784

TI Preparation of trans-6-[2-(N-heteroaryl-3,5-disubstituted
pyrazol-4-yl)-ethyl]- or -ethenyl]tetrahydro-4-hydroxypyran-2-one as
inhibitors of cholesterol biosynthesis

IN Picard, Joseph A.; Roth, Bruce D.; Sliskovic, Drago R.

PA Warner-Lambert Co., USA

SO U.S., 15 pp. Cont.-in-part of U.S. 4,808,621.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4957971	A	19900918	US 1988-280756	19881206
	US 4808621	A	19890228	US 1987-48473	19870518
	CA 1286671	A1	19910723	CA 1987-539833	19870616
	JP 63088179	A2	19880419	JP 1987-167133	19870706
	JP 07116182	B4	19951213		
	ES 2061451	T3	19941216	ES 1987-109726	19870706
	US 5102893	A	19920407	US 1990-540047	19900619
PRAI	US 1986-882327	B2	19860707		
	US 1987-48473	A2	19870518		
	US 1988-280756	A2	19881206		

OS CASREACT 114:185784; MARPAT 114:185784


IT **114433-74-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hypocholesteremic)

RN 114433-74-8 CAPLUS

CN 2H-Pyran-2-one, 6-[2-[5-(4-fluorophenyl)-3-(1-methylethyl)-1-(2-pyridinyl)-
1H-pyrazol-4-yl]ethyl]tetrahydro-4-hydroxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1988:204614 CAPLUS

DN 108:204614

TI Preparation and testing of trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl]ethyl]- or -ethenyl]tetrahydro-4-hydroxypyran-2-one derivatives as antihypercholesteremics

IN Roth, Bruce David; Sliskovic, Drago Robert

PA Warner-Lambert Co., USA

SO Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 252476	A2	19880113	EP 1987-109726	19870706
	EP 252476	A3	19891018		
	EP 252476	B1	19940202		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4808621	A	19890228	US 1987-48473	19870518
	CA 1286671	A1	19910723	CA 1987-539833	19870616
	JP 63088179	A2	19880419	JP 1987-167133	19870706
	JP 07116182	B4	19951213		
	AT 101149	E	19940215	AT 1987-109726	19870706
	ES 2061451	T3	19941216	ES 1987-109726	19870706
PRAI	US 1986-882327	A	19860707		
	US 1987-48473	A	19870518		
	EP 1987-109726	A	19870706		
OS	CASREACT 108:204614; MARPAT 108:204614				
IT	114433-74-8P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as antihypercholesteremic)				
RN	114433-74-8 CAPLUS				
CN	2H-Pyran-2-one, 6-[2-[5-(4-fluorophenyl)-3-(1-methylethyl)-1-(2-pyridinyl)-1H-pyrazol-4-yl]ethyl]tetrahydro-4-hydroxy-, trans- (9CI) (CA INDEX NAME)				

Relative stereochemistry.



L5 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1974:491517 CAPLUS

DN 81:91517

TI Aminoalkylpyrazole derivatives

IN Ueno, Katsujiro; Moroi, Tamiaki; Kojima, Hiroshi; Chiba, Tomoni

PA Daiichi Seiyaku Co., Ltd.

SO Jpn. Tokkyo Koho, 7 pp.


CODEN: JAXXAD

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 49011705	B4	19740319	JP 1970-126597	19701228
PRAI	JP 1970-126597	A	19701228		
IT	53345-79-2P 53345-80-5P 53345-81-6P 53345-83-8P 53345-85-0P 53345-86-1P 53345-87-2P 53345-88-3P 53345-89-4P 53345-90-7P 53345-91-8P 53345-92-9P 53345-93-0P 53345-94-1P 53345-95-2P 53345-96-3P 53346-00-2P 53346-01-3P				
	RL: SPN (Synthetic preparation); PREP (Preparation). (preparation of)				
RN	53345-79-2 CAPLUS				
CN	Pyrimidine, 2-[5-methyl-4-[(4-phenyl-1-piperazinyl)methyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)				




RN 53345-80-5 CAPLUS

CN Pyrimidine, 2-[4-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]-5-methyl-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 53345-81-6 CAPLUS

CN Pyrimidine, 2-[5-methyl-4-[[4-(2-methylphenyl)-1-piperazinyl]methyl]-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 53345-83-8 CAPLUS


CN Pyrimidine, 2-[4-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-5-methyl-1H-pyrazol-1-yl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 53345-82-7

CMF C20 H21 N5


10/797,244



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 53345-85-0 CAPLUS


CN Pyrimidine, 2-[4-[[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]methyl]-5-methyl-1H-pyrazol-1-yl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 53345-84-9

CMF C20 H20 Cl N5


10/797,244



CM 2


CRN 104-15-4

CMF C7 H8 O3 S




RN 53345-86-1 CAPLUS

CN Pyrimidine, 2-[4-[2-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)ethyl]-5-methyl-1H-pyrazol-1-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 53345-87-2 CAPLUS

CN Pyrimidine, 2-[5-methyl-4-[2-(4-phenyl-1-piperazinyl)ethyl]-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 53345-88-3 CAPLUS

CN Pyrimidine, 2-[5-methyl-4-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 53345-89-4 CAPLUS

CN Pyrimidine, 2-[4-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-5-methyl-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 53345-90-7 CAPLUS


CN Pyrimidine, 2-[4-[2-[4-(2-fluorophenyl)-1-piperazinyl]ethyl]-5-methyl-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 53345-91-8 CAPLUS

CN Pyrimidine, 2-[4-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-5-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 53345-92-9 CAPLUS

CN Pyrimidine, 2-[5-methyl-4-[3-(4-phenyl-1-piperazinyl)propyl]-1H-pyrazol-1-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 53345-93-0 CAPLUS


CN Pyrimidine, 2-[4-[3-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)propyl]-5-methyl-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 53345-94-1 CAPLUS


CN Pyrimidine, 2-[4-[3-[4-(4-fluorophenyl)-1-piperazinyl]propyl]-5-methyl-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 53345-95-2 CAPLUS

CN Pyrimidine, 2-[4-[3-[4-(2-fluorophenyl)-1-piperazinyl]propyl]-5-methyl-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 53345-96-3 CAPLUS


CN Pyrimidine, 2-[5-methyl-4-[3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 53346-00-2 CAPLUS

CN Pyrimidine, 2-[4-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-5-methyl-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 53346-01-3 CAPLUS
CN Pyrimidine, 2-[5-methyl-4-[3-[4-(2-methylphenyl)-1-piperazinyl]propyl]-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




10/797,244

L5 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1968:492691 CAPLUS
DN 69:92691
TI New reagent for the fluorometric determination of terbium(III) and
dysprosium(III) in aqueous solution. Bis[1(2)-pyridyl-3-methyl-5-
pyrazolonyl] -4,4'-methane
AU Butter, E.; Kolowos, I.; Holzapfel, H.
CS Karl-Marx-Univ., Leipzig, Fed. Rep. Ger.
SO Talanta (1968), 15(9), 901-11
CODEN: TLNTA2; ISSN: 0039-9140
DT Journal
LA German
IT **21645-33-0**
RL: ANST (Analytical study)
(in determination of rare earth metals)
RN 21645-33-0 CAPLUS
CN Pyrazol-5-ol, 4,4'-methylenebis[3-methyl-1-(2-pyridyl)- (8CI) (CA INDEX
NAME)



IT **21645-33-0D**, Pyrazol-5-ol, 4,4'-methylenebis[3-methyl-1-(2-
pyridyl)-, rare earth metal complexes
RL: PRP (Properties)
(spectra of)
RN 21645-33-0 CAPLUS
CN Pyrazol-5-ol, 4,4'-methylenebis[3-methyl-1-(2-pyridyl)- (8CI) (CA INDEX
NAME)



10/797,244

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

98.76

260.30

STN INTERNATIONAL LOGOFF AT 14:16:34 ON 25 JAN 2005